myrexis inc (MYRX:OTC US)
David W. Gryska MBA
Former Interim Chief Executive Officer, President, Chief Operating Officer and Director, Myrexis, Inc.
|Age||Total Calculated Compensation||This person is connected to 26 board members in 5 different organizations across 12 different industries.|
See Board Relationships
As of Fiscal Year 2013
Mr. David W. Gryska, also known as Dave, MBA, has been the Chief Financial Officer and Executive Vice President of Incyte Corporation since October 31, 2014. Mr. Gryska has been Strategic Advisor to the Board at Novogen Limited since March 3, 2014. Mr. Gryska served as an Interim Chief Executive Officer of Myrexis Inc., from August 15, 2012 to December 24, 2012. He served as the Chief Operating Officer of Myrexis, Inc., from May 11, 2012 to December 24, 2012 and served ...
630 Fifth AvenuePhone: 801-214-7800
New York, New York 10020
Board Members Memberships*
Independent Director and Chairman of Audit Committee
Director and Chairman of Audit Committee
Former Lead Director, Chairman of Compensation Committee, Member of Audit Committee and Member of Nominating & Corporate Governance Committee
Former Director, Chairman of Audit Committee and Member of Compensation Committee
Former Interim Chief Executive Officer, President, Chief Operating Officer and Director
Director and Member of Audit Committee
Director, Member of Nominating & Governance Committee and Member of Audit Committee
Golden Gate University
Loyola University of Chicago
|Richard F. Pops||Chairman of the Board and Chief Executive Officer|
|Harvey J. Berger M.D.||Principal Founder, Chairman, Chief Executive Officer, President and Chairman of Executive Committee|
Ariad Pharmaceuticals Inc.
|Jean-Jacques Bienaime MBA||Chief Executive Officer and Director|
BioMarin Pharmaceutical Inc.
|Jeffrey M. Leiden M.D., Ph.D.||Chairman, Chief Executive Officer and President|
Vertex Pharmaceuticals Incorporated
|Bruce C. Cozadd||Co-Founder, Executive Chairman and Chief Executive Officer|
Jazz Pharmaceuticals Public Limited Company
|$830.0K||Compensation as of Fiscal Year 2014.|